The WML burden and the effect of agalsidase beta @ mg/kg biweekly on WML progression were assessed longitudinally in a Phase @ agalsidase-beta placebo-controlled analysis of untreated and treated FD patients with mild-to-moderate renal involvement ( serum creatinine measurements of @ mg/dl and < @ mg/dl ) .